Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product
~ Supply Chain Now Fully Secure for PF614-MPAR ~ SAN DIEGO, CA / ACCESSWIRE / December 10, 2024 / Ensysce...
Pharmaceutical
Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS)
TORONTO, ON / ACCESSWIRE / December 10, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical...
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a...
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide...
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0)...
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
Data from Phase 1b/2 clinical trial to be presented at 2024 San Antonio Breast Cancer Symposium (SABCS) show encouraging clinical...
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
- Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis – - REGAL Independent Data Monitoring Committee...
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon and appendiceal...
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS
FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY...
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded bio-pharma companies, will assist...
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of...
NextCure Announces Acceptance of IND Application for LNCB74
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem BiosciencesBELTSVILLE, Md., Dec. 10, 2024...
Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award
Award is being presented during Advanced Therapies Week 2025 in DallasMarlborough, Massachusetts--(Newsfile Corp. - December 10, 2024) - Phio Pharmaceuticals...
Jolt Health Inc. Announces Availability of Meeting Materials
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / Jolt Health Inc. (CSE:JOLT) ("Jolt" or the "Company") announces that in...
ASBM Responds to PCMA: Put Patients First, Not PBM Profits
ARLINGTON, VA / ACCESSWIRE / December 9, 2024 / As the Senate moves this week to advance passage of the...
Martin Madaus Elected to Hologic Board of Directors
MARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #boardofdirectors--Hologic, Inc. (Nasdaq: HOLX) announced today that Martin Madaus has been elected to the Company’s Board of...
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (<45%), decreased phlebotomy use, long-term tolerability, and...
Germfree Launches Smarthood™: A Groundbreaking, Software-Agnostic IV Workflow Solution Transforming Sterile Compounding
Smarthood™ is the first solution to integrate IV workflow software, hardware, and peripherals directly into the hood enhancing best practices,...
StickIt Technologies Inc. Announces a ground-breaking new development of a medical straw for delivering vitamins to children and adults for 2025
VANCOUVER, BC, Dec. 9, 2024 /PRNewswire/ -- StickIt Technologies Inc. (the" Company "or "StickIt") (CSE: STKT), an Israeli Canadian technology...
Hot Topics in Neonatology® 2024 Conference to Feature Symposium on Clinical Impact & Cost Savings of an Exclusive Human Milk Diet
Dr. Jenny Fox From Children's Hospital of Richmond at Virginia Commonwealth University to Present Published Data and Firsthand Insights on...